AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary end

Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing

AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophil

Statistically significant and clinically meaningful disease and symptom improvements compared to pla

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) said its drug Tezspire worked in a late-stage trial of patient

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Pla

AstraZeneca said ​on Thursday ‌its asthma drug, ​Tezspire, ​developed with Amgen , ⁠met ​its main ​a

The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (dat

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharma group, has priced a €2.55 billion bond of

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharma group, has priced a €2.55 billion bond of

Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh in

BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease p

Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling, yet each company's sta

BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE

AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlike

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has retained a 'buy' rating from Citi following a mixed set of

AstraZeneca (AZN) is trading relatively stable after announcing two encouraging Phase III updates fo

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biop

AstraZeneca Plc (NYSE:AZN) on Monday reported a mix of clinical trial outcomes for its lung cancer t

AstraZeneca reports mixed lung cancer trial data, highlighting successes for Tagrisso and Enhertu wh

AstraZeneca and Daiichi Sankyo’s ENHERTU is the first and only HER2-directed medicine to improve pro

First global Phase III trial to show significant progression-free and overall survival benefits in t

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the SAFFRON Phase III trial show

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported positive results from a late-stage trial of a two

Daiichi Sankyo and AstraZeneca’s Enhertu is the first and only HER2 directed medicine to improve pro

The decision was based on the recommendation of the Independent Data Monitoring Committee, which sai

AstraZeneca on Monday said it is discontinuing ​a late stage trial ‌that tested volrustomig plus che

Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Invest

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating a

Investors need to pay close attention to AZN stock based on the movements in the options market late

https://youtu.be/H_RititNE8U

SOPHiA GENETICS (NASDAQ:SOPH) today announced a new global collaboration to develop, validate, and d

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation

Falling Oil Please click here for an enlarged chart of United States Oil ETF (NYSE:USO). N

Bristol Myers Squibb and AstraZeneca in talks for a $400B mega-merger, potentially creating the worl

Jim Cramer senses a 'fake out' in the rumored $400B AstraZeneca and Bristol Myers Squibb meg

U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lo

Atkore Inc (ATKR) shares rise on strong Q3 results and acquisition by Prysmian for $95.00 per share.

AstraZeneca in talks to merge with Bristol Myers Squibb, creating $400B pharma giant, while talks on

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datr

Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighe

U.S. stocks mixed as Dow gains 250 points amid decline in oil prices. CNN Money Fear and Greed Index

Dow Jones up 0.80% to 52,361.92, NASDAQ up 0.23% to 25,024.65, S&P 500 up 0.28% to 7,432.59. Com

AstraZeneca (AZN) Q2 2026: EPS beats estimates at $2.63 despite missing revenue targets. Oncology sa

Results in 2nd and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s c

AstraZeneca (NASDAQ:AZN) reported quarterly earnings of $2.63 per share which beat the analyst conse

https://mfn.se/cis/a/astrazeneca/astrazeneca-enhertu-plus-pertuzumab-recommended-for-approval-in-the

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

Ionis and AstraZeneca said Phase 3 eplontersen missed its primary ATTR-CM endpoint, while secondary